Healthcare Economist May 23, 2024
Jason Shafrin

Potentially so, argues Adam Fein of Drug Channels. There are two mechanisms for this. First, for drugs not covered in the maximum fair price negotiations, Fein argues that drugs with high list prices and large rebates would lead to more net savings compared to drugs with lower list price and rebates in part because in the Part D catastrophic phase, manufacturers pay 20% of gross drug cost...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Conferences / Podcast, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Trends
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes
CMS reports strong start to 2025 marketplace open enrollment, builds on record-setting success
CMS awards third round of Medicare-funded residency slots to hospitals
CMS adds 200 GME residency slots, expands physician workforce

Share This Article